6 completed, 5 active not recruiting, 3 recruiting, 3 terminated. 15 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Active not recruiting 5, Completed 5, Withdrawn 3, Recruiting 1, Terminated 1 |
| Phase 2 | 10 | Completed 4, Active not recruiting 2, Recruiting 2, Terminated 2 |
Follow Refractory Marginal Zone Lymphoma: new trials by email Literature Review of Refractory Marginal Zone Lymphoma trials Research Report on Refractory Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 1 | Withdrawn | Narendranath Epperla | 2022-07-01 | 2022-06-07 | |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Venetoclax, Lenalidomide, Rituximab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | Thomas Jefferson University | 4 | 2020-10-16 | 2026-10-02 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma Carfilzomib, Laboratory Biomarker Analysis, Rituximab - Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 2 | Terminated | University of Washington | 4 | 2017-12-18 | 2020-01-18 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab - Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 66 | 2014-05-27 | 2025-06-24 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 39 | 2013-09-24 | 2026-05-13 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2011-07-20 | 2021-10-04 |
Lymphoma, B-Cell, Marginal Zone (20) · Lymphoma, Follicular (18) · Lymphoma, Mantle-Cell (14) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, Non-Hodgkin (8) · Lymphoma, B-Cell (7) · Waldenstrom Macroglobulinemia (3) · Burkitt Lymphoma (2) · Composite Lymphoma (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Hairy Cell (1) · Leukemia, Lymphoid (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphatic Diseases (20) · Lymphoma (20) · Lymphoproliferative Disorders (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Hematologic Diseases (14) · Disease Attributes (13) · Lymphoma, B-Cell (13) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Chronic Disease (12) · Leukemia (12)
Lenalidomide (7) · CT-P10 (5) · Rituximab (5) · Cyclophosphamide (4) · Magnetic Resonance Spectroscopy (3) · venetoclax (3) · Biopsy (2) · Cytarabine (2) · Dexamethasone (2) · Hyaluronoglucosaminidase (2) · Leukapheresis (2) · Specimen Handling (2) · Stem Cell Transplantation (2) · fludarabine (2) · ibrutinib (2)
National Cancer Institute (NCI) (3) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · M.D. Anderson Cancer Center (2) · University of Washington (2) · Academic and Community Cancer Research United (1) · BeOne Medicines (1) · Joseph Tuscano (1) · Mayo Clinic (1) · Narendranath Epperla (1) · Ohio State University Comprehensive Cancer Center (1) · Thomas Jefferson University (1) · Vanderbilt-Ingram Cancer Center (1) · Yazeed Sawalha (1)
United States (17) · Australia (1) · Canada (1) · China (1) · New Zealand (1)
Joseph M Tuscano (2) · Alexey Danilov (1) · Beth A Christian (1) · Bhagirathbhai Dholaria (1) · Catherine S Diefenbach (1) · Kami Maddocks, MD (1) · Leonard T Heffner (1) · Lihua E Budde (1) · Loretta Nastoupil (1) · Mazyar Shadman (1) · Mohamed A. Kharfan-Dabaja, M.D., M.B.A. (1) · Narendranath Epperla, MD (1) · Paolo Strati, MD (1) · Phuong Vo, MD (1) · Rahul Banerjee, MD (1)
PMID 34515338, PMID 36631449, PMID 39161543, PMID 39319495
UM1CA186644 (2), 2025 (1), K24CA201524 (1), P30CA015083 (1), P30CA015704 (1), P30CA016058 (1), P30CA033572 (1), P30CA069533 (1), P30CA093373 (1), P50CA107399 (1), U01CA076576 (1), U01CA132123 (1), U10CA021115 (1), U10CA180820 (1), UM1CA186705 (1)